Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 1Q

Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira's proprietary sedation agent.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 1Q10

1Q Revenues: $1.0 billion (+17%)

1Q Earnings: $141.7 million (-14%)

Comments: Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira’s proprietary sedation agent. Global Specialty Injectables revenue was $611.4 million in the quarter, up 42%. In the Americas, revenue was $483.9 million (+45%). In Europe, Middle East & Africa sales were $69.9 million (+21%). In Asia Pacific sales were 57.6 million (+48%). Contract manufacturing revenues are not broken out.

Click here to learn more about Hospira.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics